Reductive Incubation for Scalable Heterodimeric Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods face challenges in producing bispecific antibodies on a large scale by optimizing manufacturing processes.
Innovation Solution
A method involving the combination of homodimeric antibodies with differing CH3 regions, followed by incubation with a reducing agent and ambient dissolved oxygen, or controlled oxygen levels, to form heterodimeric antibodies without measuring or controlling oxygen percentage, enhancing the heterodimeric interaction strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods are used to produce bispecific antibodies, then manufacturing process optimization is achieved, but large-scale production remains challenging
Solution Approach 1:
The patent changes the chemical parameter of the incubation environment by using reducing agents to break disulfide bonds, enabling heterodimeric antibody formation. This parameter change allows for simplified large-scale production by eliminating the need for complex oxygen control systems while achieving stable heterodimeric interactions through controlled chemical modification.
2Manufacturing precision
If oxygen control steps are implemented during antibody production, then oxidation control is improved, but process complexity and cost increase
Solution Approach 1:
The patent extracts and eliminates the need for oxygen control mechanisms from the production process. By using reducing agents to control the oxidation state during incubation, the method removes the requirement for complex oxygen monitoring and adjustment equipment, thereby simplifying the overall system while maintaining manufacturing precision.
Solution Approach 2:
The patent introduces reducing agents as intermediary substances to mediate the oxidation control function. Instead of directly controlling oxygen levels in the environment, the reducing agents serve as chemical intermediaries that control the oxidation state of the antibody molecules during incubation, achieving the same outcome with simpler equipment.
3Stability of the object's composition
If heterodimeric interaction strength is increased, then antibody stability is improved, but production yield may be affected
Solution Approach 1:
The patent changes the chemical environment parameters by introducing reducing agents during incubation, which facilitates the formation of stable heterodimeric interactions. This parameter change enhances antibody stability while maintaining production yield by using controlled chemical conditions rather than complex physical processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates the production of stable heterodimeric antibodies at scale, improving manufacturing efficiency and yield.
Implementation Method 1
incubating the mixture in the presence of a reducing agent and ambient dissolved oxygen (DO2) to produce the heterodimeric antibody
Implementation Method 2
incubating the mixture in the presence of a reducing agent and ambient dissolved oxygen (DO2) to produce the heterodimeric antibody
Data Source
AI summary
The invention relates to methods of producing heterodimeric antibodies.